Results for this period
Full year1 July 2025 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the DTx Product Business, the Company received milestone payments of ¥240 million for a tinnitus treatment app and ¥100 million for a treatment app for premenstrual syndrome and other conditions, and launched insurance coverage and sales of an insomnia disorder app. In the DTx Platform Business, revenue remained stable, supported by continued use of the machine-learning automated analysis system.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 July 2025 to 30 June 2026 |
| Net Sales | ¥497 million (YoY +7.4%) |
| Operating profit | ¥-330 million |
| Ordinary income | ¥-325 million |
| Profit attributable to owners of the parent | ¥-382 million |
| Net income per share | ¥(22.71) |
| Operating Margin | Current fiscal year -66.4 % / Previous period -64.7 % |
| Equity ratio | End of the current fiscal period 94.2 / End of previous period 96 |
| Total assets | ¥4,218 million |
| Net assets | ¥4,070 million |
| Cash flows from operating activities | ¥-474 million |
| Cash flows from investing activities | ¥-228 million |
| Cash flows from financing activities | ¥2 million |
| Cash and cash equivalents at end of period | ¥3,698 million |
| Full-year earnings forecast | Net Sales ¥838 million (YoY +68.7%) / Operating profit ¥-461 million / Ordinary income ¥-474 million / Net income ¥-541 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | DTx product business ¥340,234 thousand (YoY +13.4%) / DTx platform business ¥156,977 thousand (YoY -3.7%) |
| Segment profit | DTx product business ¥103,418 thousand (YoY -12.4%) / DTx platform business ¥76,958 thousand (YoY +132.3%) |
| Depreciation and amortization | ¥10,174 thousand |
| Impairment loss | ¥67,471 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥7,747 thousand, Reversal of asset retirement obligations ¥6,389 thousand / Extraordinary loss Impairment Losses ¥67,471 thousand, Other ¥26 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | At a meeting of the Board of Directors held on 22 July 2026, the Company resolved to issue 1,330 stock acquisition rights as stock options for 43 employees, representing 133,000 underlying shares, and completed the allotment on 7 August 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 16,868,100 Shares |
| Treasury Shares at Period-End | 6,244 Shares |
| Factors Behind Changes in Business Performance | In the DTx Product Business, the Company received milestone payments of ¥240 million for a tinnitus treatment app and ¥100 million for a treatment app for premenstrual syndrome and other conditions, and launched insurance coverage and sales of an insomnia disorder app. In the DTx Platform Business, revenue remained stable, supported by continued use of the machine-learning automated analysis system. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the DTx Product Business, milestone revenue was received for a tinnitus treatment app and a treatment app for premenstrual syndrome and other conditions, and insurance coverage and sales were launched for an insomnia disorder app. For corporate assets, the Company recognized an impairment loss of ¥67.471 million because operating cash flow had remained negative and total undiscounted future cash flows were expected to fall below the assets' carrying amount.